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Abstract
Gene therapy is currently considered as the optimal treatment for inborn errors of
metabolism (IEMs), as it aims to permanently compensate for the primary genetic
defect. However, emerging gene editing approaches such as CRISPR-Cas9, in which
the DNA of the host organism is edited at a precise location, may have out-
performing therapeutic potential. Gene editing strategies aim to correct the actual
genetic mutation, while circumventing issues associated with conventional compen-
sation gene therapy. Such strategies can also be repurposed to normalize gene
expression changes that occur secondary to the genetic defect. Moreover, besides the
genetic causes of IEMs, it is increasingly recognized that their clinical phenotypes
are associated with epigenetic changes. Because epigenetic alterations are principally
reversible, this may offer new opportunities for treatment of IEM patients. Here, we
present an overview of the promises of epigenetics in eventually treating IEMs. We
discuss the concepts of gene and epigenetic editing, and the advantages and disad-
vantages of current and upcoming gene-based therapies for treatment of IEMs.
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DNA methylation, (epi)genome editing, gene correction, histone modifications, inherited metabolic
disease, therapy development
Compensating the primary genetic defect is currently consid-
ered as the ultimate treatment strategy for inborn errors of
metabolism (IEMs). In conventional gene therapy, a vector
containing the correct coding DNA (cDNA) sequence of the
defective gene is delivered into the host.1 This method actu-
ally represents a compensation approach, as the endogenous
genetic defect is not corrected. Gene therapy has been suc-
cessfully applied in preclinical models for IEMs, including
glycogen storage disease type 1a (GSD Ia; OMIM #232200),
familial hypercholesterolemia (OMIM #143890), hemophilia
B (OMIM #306900), ornithine transcarbamylase (OTC; EC
2.1.3.3) deficiency (OMIM #311250), hereditary tyrosinemia
type 1 (HT1; OMIM #276700), and alpha-1 antitrypsin defi-
ciency (OMIM #613490).2–4 As a consequence of these
successes, various gene therapy trials are currently ongoing.
For example, recently, a human phase 1/2 trial has started in
adult GSD Ia subjects (NCT03517085). The ultimate goal of
such viral gene therapy is to restore production of the func-
tional protein for sustained periods. For those IEMs in which
the corrected proteins should be either secreted by or
expressed in easily transduced cells (eg, hepatocytes),5 gene
therapy would indeed provide a realistic cure if the transgene
insertion could be targeted to harmless sites in the genome.
However, when using conventional viruses, the lack of inte-
gration control may cause insertional mutagenesis and conse-
quently severe side effects such as cancer.
Next to these safety considerations, conventional com-
pensatory gene therapy has several other disadvantages.
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First, the size limitation of cDNA that can be cloned into a
viral vector may compromise viral therapy for genes with a
long coding sequence. Second, lack of control over expres-
sion of the newly introduced cDNA might compromise ther-
apy effectiveness. Third, the need for multiple vectors to
express different isoforms of the gene (or the selection of
one specific cDNA isoform for transfer) might compromise
gene therapy for certain diseases. For example, when a
mutation affects multiple isoforms of the same protein with
tissue-selective expression, as is the case in
hyperammonemia (OMIM #6126652 / #219150),6 a combi-
nation of viral vectors would be needed to correct the dis-
ease. Thus, although compensation gene therapy can provide
an actual cure for IEMs, its disadvantages urge the explora-
tion of alternative therapeutic opportunities.
Gene editing refers to modification of the DNA sequence
at a precise genomic location. This approach involves differ-
ent DNA targeting techniques such as meganucleases
(MNs), zinc finger nucleases (ZFNs), transcription activator
like effector nucleases (TALENs), and the currently widely
used clustered regularly interspaced short palindromic
repeats (CRISPR)-Cas9 system, which all alter the genome
of the host organism at the locus of choice7–9 (Figure 1).
MNs are endodeoxyribonucleases, proteins with the capacity
to recognize a 12-40 base pair double-stranded DNA-
sequence and cut DNA. ZFNs and TALENs both consist of
transcription factor-based DNA-binding domains fused to a
nuclease. With ZFNs, each zinc finger protein (ZFP) recog-
nizes a three base pair-DNA sequence. In the case of
TALENs, each TAL protein consists of 34 amino acids, with
amino acids 12 and 13 determining the recognition of one
specific DNA base pair. By using multiple ZFNs or
TALENs, a longer DNA sequence can be targeted, thereby
increasing specificity. In contrast to MNs, ZFNs, or
TALENs, CRISPR-Cas9 uses a RNA-based DNA-binding
strategy. The CRISPR-Cas9 system consists of a single-
guide RNA (sgRNA) and the Cas9 protein. The sgRNA is a
combination of CRISPR RNA(s) (crRNA[s]) and a trans-
FIGURE 1 Schematic overview of the three main gene editing tools. A, Zinc finger nuclease (ZFN), consisting of a DNA-cutting nuclease
domain (gray box), and a protein-based DNA-binding domain of three zinc finger proteins (colored circles), each recognizing a three base pairs
(bp) DNA sequence. Hence, this ZFN recognizes a 9 bp genomic sequence. B, Transcription-activator like effector nuclease (TALEN), consisting of
a DNA-cutting nuclease domain (gray box), and a protein-based DNA-binding domain of 18 TAL effector repeats. Each TAL effector consists of
34 amino acids, typically highly conserved, with positions 12 and 13 being variable and determining the specific recognition of one DNA
bp. Hence, this TALEN recognizes a 18 bp genomic sequence. C, Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system,
consisting of a DNA-cutting nuclease (gray box), with two sites of nuclease activity, and a RNA-based DNA-binding domain consisting of a single
guide RNA (sgRNA), with the variable 20 nucleotide RNA-sequence determining recognition of a 20 bp complementary genomic sequence
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activating crRNA of the original class II CRISPR-Cas9 sys-
tem, including a ~20 nucleotide RNA sequence that can be
designed complementary to a specific location in the
genome. The sgRNA guides the Cas9 nuclease to virtually
any desired genomic location, after which Cas9 creates a
DNA double-strand break (DSB) at this targeted site.
Gene editing–induced DSBs are subsequently repaired
by either non-homologous end joining, usually resulting in
inserts or deletions (indels) causing mutations and often a
dysfunctional protein, or by homology directed repair
(HDR). When a DNA repair template is present, HDR can
insert (part of) a gene, or correct a mutated gene. Especially
this latter option is of particular interest for treating IEMs
because it enables the endogenous correction of the genetic
defect of the IEMs in a one-and-done approach. This over-
comes several downsides of gene therapy: it repairs the gene
mutation at the endogenous site, rather than providing the
cell with the entire cDNA sequence of the correct gene in a
random location; the expression of the gene is under its
endogenous control, as opposed to uncontrollable cDNA
expression with conventional gene therapy; and finally, the
correction of the mutation is expected to result in expression
of all potential isoforms of the gene. The recently introduced
CRISPR-Cas9 technique is currently more widely used than
ZFNs or TALENs because of the distinction between the
DNA-recognition domain (sgRNA) and the nuclease domain
(Cas9), which makes it time- and cost-effective to use.
Targeting other genes only requires design of additional
sgRNAs without the need to engineer different nuclease
fusions. To date, CRISPR-Cas9 has already been success-
fully used in various in vitro studies and in vivo animal
models. In preclinical models for IEMs including OTC defi-
ciency, HT1, mucopolysaccharidosis type II (MPS II;
OMIM #309900), and GSD Ia,3,10–13 ZFNs and CRISPR-
Cas9 techniques have been used to correct the mutated gene
or insert the correct cDNA. These techniques have prog-
ressed to clinical trials, for instance to treat lung cancer
patients (OMIM #211980) by administration of their own T
cells after these were isolated and genetically modified
ex vivo.14 Recently, the first test of in-body (in vivo) ZFN
gene editing in humans has shown encouraging results by
inserting a healthy copy of the iduronate-2-sulfatase (IDS,
EC 3.1.6.13) gene into liver cells to treat MPS II.15
The main advantage of gene editing techniques is evident
as IEMs can be corrected, rather than compensated, at the
root: the actual genetic defect. In case the corrected protein
is secreted, the genetic modification only needs to take place
in a limited amount of cells. However, gene editing tech-
niques also pose several important downsides that currently
limit their clinical potential. Most importantly, gene editing
may induce a p53-mediated immune response16 and poten-
tial off-target effects.17 Although it is currently difficult to
accurately and efficiently predict the frequency and severity
of off-target effects, also because chromatin environments
are different in different cell types,18 specificity of gene
editing remains critical considering that DNA alterations are
maintained life-long. Especially when off-target effects
occur in the germline, transmission to offspring may result
in unforeseen detrimental consequences.19 As a conse-
quence, gene editing tools such as CRISPR-Cas9 are a fre-
quent topic of (moral) discussion, particularly after the
recent birth of the first two human genome-edited babies.20
Thus, although correction of the primary defects in IEMs
would be preferred, the downsides of the available gene
editing techniques stress the need for alternative therapeutic
approaches. In this respect, it should be emphasized that
IEM pathophysiologies are generally not solely related to
the primary genetic defects, but also to the subsequent adap-
tations by the patient's cells and organs. This is exemplified
by the lack of genotype-phenotype correlations in certain
IEMs,21–26 illustrating the relevance of alternative mecha-
nisms, such as epigenetics, to explain clinical heterogeneity
between patients.27,28 Thus, the distinction between the pri-
mary genetic defect and the subsequent adaptations is impor-
tant, as it may allow for different, yet complementary,
effective therapeutic approaches that aim beyond the pri-
mary defect. To distinguish between these two aspects, we
refer to altered intracellular/extracellular metabolite levels,
aberrant cellular signaling, or gene expression dys-
regulation29 as the secondary adaptations. There are multiple
ways to interfere with secondary adaptations, for instance by
targeting the intracellular and extracellular levels of metabo-
lites and cofactors, by restoring aberrant cellular signal trans-
duction pathways, and/or by means of gene expression
regulation. Treatment of IEMs via reversal of the down-
stream effects of a genetic mutation can be achieved through
correction of aberrant expression levels of disease-associated
genes. In this respect, gene editing tools can be used to mod-
ify gene expression levels by inactivating the DNA nuclease
domain. One way to repurpose gene targeting tools is
through fusion of epigenetic effector domains to the
nuclease-inactivated DNA-binding platforms to modulate
epigenetic signatures.
Epigenetics refers to the study of heritable changes in the
phenotype that do not involve changes in the DNA
sequence, but concerns alterations in DNA methylation and
modifications of histones, hence affecting gene expression.
For example, DNA methylation of a gene promoter gener-
ally leads to lower expression of that gene. Histone acetyla-
tion generally results in a loosened chromatin structure and
thus increased gene transcription, while histone methylation
can have both repressing or activating roles based on the
amino acid of the histone that is modified. Besides acetyla-
tion and methylation, multiple other forms of histone
RUTTEN ET AL. 65
modifications exist, including phosphorylation,
SUMOylation, ubiquitination, and, perhaps more relevant
for IEMs, citrullination, ADP-ribosylation, O-glycosylation,
succinylation, and malonylation.30 In addition, metabolic
activities are directly linked to DNA and histone modifica-
tions.31 For example, acetyl-coA is a central metabolite that
also serves as co-substrate in histone acetylation, levels of
nicotinamide adenine dinucleotide (NAD+) affect sirtuin-
dependent histone deacetylation, S-adenosyl-methionine and
S-adenosyl-homocysteine regulate histone and DNA methyl-
ation, and mitochondrial oxidative metabolism is closely
linked to histone demethylation.31 Considering this associa-
tion between DNA/histone modifications and metabolism,
epigenetics might provide a link between genetic defects and
clinical phenotypes and may offer novel opportunities for
refined diagnostics and treatments of IEMs with great poten-
tial. Although still a nascent field, the importance of epige-
netics in IEMs is increasingly recognized, as exemplified by
a review on the role of epigenetics in lysosomal storage dis-
orders.27 Altogether, IEMs are associated with epigenetic
changes, and epigenetics represents an interesting novel field
for the treatment of IEMs.
Because epigenetic changes influence gene expression regu-
lation, they can be targeted to correct or compensate aberrant
gene expression in IEMs, with similar outcomes as gene ther-
apy and gene editing. Several epigenetic drugs (“epi-drugs”)
have already been FDA approved, and in the oncology field
numerous clinical trials with such compounds are currently
ongoing,32 reflecting the promising therapeutic potential of
targeting epigenetics. The main disadvantage of epi-drugs,
however, is the fact that they act genome-wide rather than in a
gene-specific manner, increasing potential unwanted side
effects and thereby limiting wide clinical applications. A tech-
nique that appears to be very suitable for safe, yet stable, thera-
peutic modulation of gene expression (as well as for
compensation/alleviation of genetic mutations) is epigenetic
editing (EGE,33–35). By combining epigenetic enzymes with
the advantages of DNA-targeting techniques, EGE directly
exploits the reversibility of epigenetic changes in a gene-
specific manner. EGE is based on the programmable DNA-
binding platforms (ZF proteins [ZFPs], TALEs, or CRISPR-
Cas9), where the nuclease activity is removed or deactivated,
thereby preventing manipulations of the DNA sequence.
Rather, the DNA-binding protein (ZF/TALE) or the deactivated
nuclease (“dead” Cas9, or dCas9, in case of CRISPR-[d]Cas9)
serves as a “shuttle” protein to which other proteins can be
fused, including artificial transcriptional activators, repressors,
or other (co)factors involved in expression regulation, that
allow transient gene expression modulation (Figure 2). In the
case of EGE, epigenetic enzymes are fused to the deactivated
nuclease to reprogram epigenetic signatures. These enzymes
can be epigenetic writers, such as DNA methyltransferases or
histone lysine- or methyltransferases, or epigenetic erasers,
such as enzymes involved in removing DNA methylation or
histone deacetylases/demethylases. EGE thus provides an
innovative approach to not only study chromatin biology and
causality in gene expression regulation, but also to ultimately
potentially be used as a therapeutic tool.
EGE overcomes several downsides of the other
approaches discussed earlier. Gene expression modulation
via EGE, for example with a single sgRNA and an epige-
netic enzyme fused to dCas9, achieves a natural, endogenous
expression control, more closely mimicking nature than
cDNA overexpression, inducing/targeting all isoforms, and
without issues related to size. In some cases, epigenetic
changes are mitotically stable,36,37 implying a sustained ther-
apeutic effect, and rendering the technique of EGE a one-
and-done approach, similar to gene editing. Although similar
to gene editing tools EGE might suffer from off-target
effects, the reversible nature of epigenetic changes allows
for relative easy correction of these unwanted effects. So,
while on one hand epigenetic changes can be actively over-
written by EGE, these changes can subsequently be copied
during cell divisions, allowing stable effects. Indeed, during
differentiation of cells, epigenetic signatures are rewritten to
stably program the cell type-specific gene expression pro-
files. These epigenetic signatures are subsequently copied to
daughter cells during mitosis, ensuring the maintenance of
cell identity. Despite this epigenetic memory, cells can adapt
their epigenetic signatures in response to prolonged environ-
mental changes. This adaptation of cells indicates the
dynamics of epigenetics and is reflected in a common defini-
tion of epigenetics: heritable, yet reversible, changes in gene
expression, not encoded in the DNA sequence. In EGE, the
forced presence of an epigenetic writer or eraser at a geno-
mic locus changes the epigenetic signature. Such changes
can be copied/maintained by the epigenetic maintenance
enzymes, allowing stability of the newly introduced mark.
Given this characteristic of epigenetic changes, EGE is gen-
erally considered safer than gene editing, as no genetic
changes are introduced, but might be equally effective, as
stable expression modulation can be achieved.36–38
There are several examples of successful application of
EGE using ZFs and CRISPR-dCas9 in preclinical models.
Research has shown that EGE can be applied in a gene-
specific manner for DNA (de)methylation and histone
modifications, and that these changes might translate into
physiological changes.37,39–46 EGE is also potentially inter-
esting for the treatment of IEMs. For example, reducing
PCSK9 in familial hypercholesterolemia expression may
reduce plasma cholesterol levels.3 In addition, EGE can also
be applied in IEMs to increase the expression of a mutated
protein with residual activity. In case of complete loss-of-
function mutations, EGE may be instrumental to increase the
66 RUTTEN ET AL.
expression of proteins that compensate for the defect. Exam-
ples of IEMs where this strategy may be powerful include
hereditary fructose intolerance (OMIM #229600), in which
the isozyme aldolase A (EC 4.1.2.13) might be upregulated
to correct for aldolase B enzyme deficiency,47 and GSD Ia,
where the lysosomal α-glucosidase (EC 3.2.1.20 and EC
3.2.1.33) could be increased to enhance glucose-
6-phosphatase (EC 3.1.3.9) (G6Pase)-independent glucose
production.48 Thus, the fact that epigenetic changes play a
role in IEMs27, are reversible, and may arise later in life as a
consequence of the IEM and could potentially contribute to
long-term complications of the disease, makes EGE also an
interesting tool to prevent or compensate for these complica-
tions, such as the development of cancer in IEM patients.29
Each approach discussed in this review has its specific
advantages and disadvantages (Table 1). One of the major
challenges of all methods involves the efficient delivery of
the therapy's components. Delivery can be accomplished in
different ways, for example, by using plasmids, adenovirus,
retrovirus, lentivirus, adeno-associated virus, or ribonuclear
methods. Although an extensive discussion of this issue is
beyond the scope of this review, it is important to stress that
therapy delivery is expected to further improve in the near
future.1 Related to the issue of efficient delivery is the risk
for an immune response to gene therapy and gene/epigenetic
editing, which further challenges delivery efficiency and
sustained therapeutic effectiveness. Ongoing and future
research will elucidate if sufficient progress can be made to
circumvent this issue.
In conclusion, while conventional compensation gene
therapy using cDNA is currently the preferred treatment for
IEMs, there are several challenges that may hamper its clini-
cal application. Corrective gene editing circumvents many
of the issues, as it repairs the genetic defect permanently,
overcoming the need for the introduction of a full-length
exogenous cDNA sequence. However, the main disadvan-
tage of gene editing is the risk for off-target effects with irre-
versible alterations in the genomic sequence, which can
become particularly harmful when occurring in the germline.
EGE represents a less invasive, yet potentially stable thera-
peutic approach. It allows for reversible alterations in DNA
methylation and histone modifications in a gene-specific
FIGURE 2 Comparison of different strategies to treat IEMs. A, Conventional gene therapy, based on the introduction of a cDNA or mRNA
sequence encoding a correct version of the mutated gene. As a result, the defect is compensated without altering the genomic sequence of the
host. B, Gene editing using (in this case) CRISPR-Cas9, which aims to correct the mutated gene by altering the genomic sequence of the host at a
precise location, or which can be used to modify the expression of proteins that compensate for the genetic defect via alterations in the genome. C,
Epigenetic editing using an epigenetic writer or erasers fused to (in this case) the CRISPR-dCas9 system to compensate for the genetic defect, for
example, by increasing the residual expression of a mutated protein to enhance its activity, or by modifying the expression of proteins capable of
compensating for the genetic defect, via gene-specific alterations in the epigenetic landscape
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manner, hence reprogramming gene expression profiles in
IEMs with clear advantages over conventional gene therapy
and gene editing. Compared with gene editing, EGE is con-
sidered safe because it does not lead to alterations in the
genome, but to modifications in the epigenome. Because
such modifications are in principle reversible, correction of
potential off-target effects seems more feasible. Altogether,
epigenetics is a relatively unexplored field in the pathophysi-
ology of IEMs, while metabolic activity is directly related to
epigenetic enzyme activity and epigenetic marks on DNA
and histones. EGE has clear advantages over gene therapy
or gene editing approaches and thus provides a potentially
valuable and novel approach to treat IEMs.
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